Forcefield Therapeutics appoints John Tsai MD as Chief Executive Officer John will lead the company as CEO to explore the potential of a novel therapeutic for treatment of acute heart attacks into clinical developmentThis novel protein technology has been shown in...

Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics Agreement grants Freeline rights to develop and commercialise AAV gene therapies using cardiac...

Forcefield Therapeutics presents positive preclinical data at the 2022 Scientific Sessions of American Heart Association Forcefield Therapeutics presents positive preclinical data at the 2022 Scientific Sessions of American Heart Association Preclinical data outlining the mechanisms of three proteins shown to restore...

Researchers identify three proteins which have the potential to prevent heart failure after heart attack Researchers identify three proteins which have the potential to prevent heart failure after heart attack Publication in Science Translational Medicine describes three proteins which have been shown...

Forcefield Therapeutics launches today following £5.5m commitment from Syncona Forcefield Therapeutics launches today following £5.5m commitment from Syncona New biotechnology company launched to develop pioneering, best-in-class therapeutics to protect heart function...